Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bridgebio Pharma Inc
(NQ:
BBIO
)
27.49
-0.18 (-0.65%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,482,596
Open
27.68
Bid (Size)
26.50 (3)
Ask (Size)
27.70 (3)
Prev. Close
27.67
Today's Range
27.00 - 28.28
52wk Range
21.62 - 44.32
Shares Outstanding
160,500,999
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Today 7:18 EST
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 25, 2024
Via
Benzinga
Performance
YTD
-32.04%
-32.04%
1 Month
+11.66%
+11.66%
3 Month
+2.00%
+2.00%
6 Month
-5.21%
-5.21%
1 Year
-21.90%
-21.90%
More News
Read More
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
November 25, 2024
Via
Benzinga
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
November 25, 2024
Via
Benzinga
Topics
Economy
Exposures
Fossil Fuels
Interest Rates
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
November 25, 2024
Via
Benzinga
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
November 25, 2024
Via
Investor's Business Daily
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
November 25, 2024
Via
Benzinga
Exposures
Product Safety
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
November 22, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
November 19, 2024
Via
Benzinga
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
November 18, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
November 18, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
November 12, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
November 05, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
October 24, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
3 Top Stocks That Could Still Rocket Higher in 2024
October 04, 2024
Via
The Motley Fool
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
October 03, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
September 30, 2024
Via
Benzinga
Exposures
Product Safety
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
September 30, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
September 27, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
September 17, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition
September 11, 2024
Via
Benzinga
BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
September 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
September 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Patchy And Still Patchy In The Short Term
September 09, 2024
Via
Talk Markets
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.